Noviello, D.Chaparro, M.Viganò, C.Blesl, A.Barberio, B.Yanai, H.Macaluso, F.Iglesias, R. FerreiroBezzio, C.Zilli, A.Molnár, T.Gheorghe, C.Conforti, F. S.Innocenti, T.Saibeni, S.Bossuyt, P.Oliveira, R. F. deGabrielli, A. M. CarvalhasLosco, A.Vieujean, S.Tettoni, E.Pirola, L.Calderone, S.Cohen, M. KornowskiDragoni, G.Rath, T.Acosta, M. Barreiro-deSavarino, E. V.Gisbert, J. P.Vecchi, M.Atreya, R.Caprioli, F.2025-03-072025-03-072025-011873-99461876-4479http://hdl.handle.net/10400.1/26878Inflammatory bowel disease (IBD) patients with Clostridiodes difficile Infection (CDI) are at increased risk of disease exacerbations, therapy escalation, colectomy, and mortality. Data on fidaxomicin use in IBD patients with CDI are very limited. We aimed to assess the effectiveness and safety of fidaxomicin for CDI and its impact on IBD outcomes in a large retrospective multicenter cohort studyengconference object10.1093/ecco-jcc/jjae190.1330